OBJECTIVE: While surgical procedures are associated with persistent opioid use, it is unclear whether this is due to procedures themselves or subsequent opioid exposure. To examine this question, we compared persistent opioid use after cesarean delivery (CD) and vaginal delivery (VD), procedures associated with differential opioid prescribing. STUDY DESIGN: We included women 15-44 years enrolled in TN Medicaid with no opioid use 180 days prior to a delivery from 1/1/ 2007 to 9/30/2015. We defined exposure groups based on filled opioid prescriptions (Rx) during the postpartum period (42 days): no Rx, discharge Rx only (>¼1 Rx fill from delivery to day 7 and no Rx fill days 8-42), or second Rx (>¼1 Rx fill from delivery to day 7 and >¼1 Rx fill days 8-42). Our outcome was persistent opioid use, defined as >¼1 Rx fill in each 45-day period from 43-365 days after delivery. We then compared differences in persistent opioid use by delivery type and opioid Rx exposure. RESULTS: Of 125542 women, 89.2% of women with CD and 54.4% with VD filled at least one Rx during the postpartum period. More women with CD versus VD filled a discharge Rx (70.3% vs 43.7%) and a second Rx (17.2% vs 6.5%). See Table. Overall, 701 (0.68%) women had persistent opioid use, which was higher among women who underwent CD compared to VD (0.84% vs 0.53%, RR 1.61, 95%CI 1.42-1.90). However, within each Rx exposure category, persistent use was either the same or lower among women with CD compared to VD: No Rx, RR 1.06 (0.42-2.67); discharge Rx, RR 0.75, (0.57-0.98); second Rx, RR 0.68 (0.56-0.83). Compared to women with no Rx after VD, persistence was significantly higher among women with discharge Rxs ) and women with second Rxs ). Compared to women with no postpartum Rx after CD, persistence was significantly higher among women with discharge Rxs only ), and women with second Rxs (RR 24.07,). These findings remained after excluding women with complicated vaginal deliveries or severe maternal morbidity, and after adjusting for demographic covariates, pain conditions, and morbidities associated with delivery. CONCLUSION: Opioidprescribing after delivery is associated with increased risk of persistent opioid use, with only modest differences by delivery type. Women who fill second prescriptions, whether undergoing CD or VD, represent a group at high risk for persistent opioid use.
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OBJECTIVE:
The obstetric comorbidity index (OBCMI) is a claimsdata derived maternal risk-assessment tool that summarizes the burden of maternal comorbidities into a single numerical score. Though validated in external database populations, the clinical utility of the score to triage high-risk women at risk of adverse outcomes has yet to be explored. The aim of this study was to prospectively validate a clinical modification of the OBCMI as a maternal risk assessment tool for predicting severe maternal morbidity (SMM). STUDY DESIGN: All patients with pregnancies at or beyond 23 weeks gestation presenting to labor and delivery (L&D) from February to June 2018 were included in the study. The admitting L&D nurse assessed patient comorbidities and calculated the patient's OBCMI (Table) . The score was recalculated at each 12-hour shift change. A multidisciplinary panel of clinicians determined whether patients experienced SMM based on the ACOG/SMFM consensus definition, blinded to the patient's OBCMI score. We analyzed association between the OBCMI score and the occurrence of SMM and calculated a c-statistic to define the discrimination of the score. RESULTS: Two thousand ninety-one women were included, of whom 1.75% developed SMM (n¼40). The prevalence of the individual comorbidities comprising the score are presented in the Table. The median OBCMI score for women experiencing the primary outcome was 5 (IQR 2.0-7.5) compared to a median score of 1 (IQR 0-3) for those without SMM (p<0.01). The frequency of SMM increased from 0.39% for those with a score of 0 to 21.4% for those with a score greater than or equal to 9 (Figure) . For every one point increase in the score patients experienced a 1.53 increase in odds of SMM (95% CI 1.39-1.69). The c-statistic for the OB-CMI score was 0.80. CONCLUSION: The OBCMI score can prospectively identify women at risk of severe maternal morbidity in a clinical setting. Routine use of the OBCMI score has the potential to identify at-risk women warranting increased surveillance or transfer of care in an attempt to prevent adverse maternal outcomes.
